Becampanel, formerly known as AMP-397, is an AMPA receptor antagonist potentially for the treatment of epilepsy. Becampanel acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM). It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials. References: Jahnke W, Bold G, Marzinzik AL, Ofner S, Pellé X, Cotesta S, Bourgier E, Lehmann S, Henry C, Hemmig R, Stauffer F, Hartwieg JC, Green JR, Rondeau JM. A General Strategy for Targeting Drugs to Bone. Angew Chem Int Ed Engl. 2015 Nov 23;54(48):14575-9. doi: 10.1002/anie.201507064. PubMed PMID: 26457482.

纯度：≥98%

CAS：188696-80-2